K T Rama Rao unveils BE's 300 Crore plant at Hyderabad

▴ K T Rama Rao unveils BEs 300 Crore plant at Hyderabad
Hyderabad based pharmaceutical co. Biological E Ltd.recently launched its new plant of Rs.300 crores at Genome Valley. This initiative will enhance the production and manufacture of new vaccines.

Pharmaceutical company Biological E. Limited on 17.02.2020 launched its new plant, built with an investment of Rs. 300 crore at Genome Valley here.Telangana's Industry Minister K.T. Rama Rao inaugurated the facility, which will generate employment for about 1,000 people.

Mahima Datla, Managing Director, Biological E. Limited, this new facility will help their existing vaccines plant enhance the production and manufacture new products, which are in the pipeline.The plant has come up on 29 acres in the Special Economic Zone at Genome Valley in Kolthur village on the outskirts of Hyderabad.

Kiran Mazumdar Shaw, Chairperson and Managing Director, Biocon, Professor Baron Peter Piot, Director, London School of Hygiene and Tropical Medicine were also present.

Rao said the government was committed to make Telangana number one state in terms of industrial growth and employment generation with a special focus on life sciences.Rama Rao also unveiled BE's Typhoid Conjugate Vaccine. Recently, BE received the authorisation from the health regulatory authorities of India to license and market TCV.

TCV is an injectable single-dose vaccine to be administered to children of the age of above 6 months as well as adults. The clinical studies conducted in India demonstrated that the safety and immunogenicity profiles of this vaccine are comparable to the other licensed and WHO Pre-qualified Typhoid conjugate vaccine, Biological E. said.

This vaccine was developed in partnership with the GSK Vaccines Institute for Global Health, based in Siena (Italy), which first developed the asset and transferred it to BE in 2013. Subsequent developmental work on the vaccine was done by BE, including manufacturing process optimization and scale up, pre-clinical studies and full clinical trials in India.

This vaccine will be manufactured in BE's GMP manufacturing facilities in Hyderabad, India and could be commercially available within 3 months, it added.

Story Source : IANS

Tags : #Ktramarao #Hyderabadbasedbiologicaleltd #Typhoidconjugatevaccine #Gskvaccineinstitute

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Cancer on the Menu: How Excess Salt is Quietly Killing Your StomachDecember 03, 2024
Breaking Barriers: Honouring the International Day of Persons with Disabilities December 03, 2024
Invisible Threat: How Air Pollution is Impacting Pregnancies and Shaping Future GenerationsDecember 03, 2024
Medanta Gurugram successfully treats ‘rarest of rare’ lymph node cancer resistant to other drugs using CAR-T Cell TherapyDecember 03, 2024
Nonin Medical secures FDA clearance for its over-the-counter fingertip pulse oximeter, accurate for patients of all skin colorsDecember 02, 2024
ALARM 2024: Amrita Leads the Fight Against Antimicrobial ResistanceDecember 02, 2024
Coral adaptation unlikely to keep pace with global warmingDecember 02, 2024
Reaching the unreached to find missing TB casesDecember 02, 2024
Sip Smart: Why Changing Your Water Habits Can Change Your LifeNovember 28, 2024
Can Your Fingers Predict How Much You Drink? New Study ExplainsNovember 28, 2024
India Leads Global Medical Tourism with 8% Share; PSRI Sets New Benchmarks with nearly 15% International Patient BaseNovember 28, 2024
Medicines save lives but not when they stop workingNovember 28, 2024
A total of 340 Children Participated in the Painting Competition Organized by Asian HospitalNovember 28, 2024
The Standing Desk Myth: Is Sitting Actually Healthier?November 27, 2024
How Cancer Outsmarts Chemotherapy: The Hidden Metabolic GameNovember 27, 2024
Aakash Healthcare Saves life of a 61-year-old Women through Timely Neuro-intervention with a multi-disciplinary management of StrokeNovember 27, 2024
Breakfast Wars: Why Men and Women Should Eat DifferentlyNovember 27, 2024
Only 10% of Businesses Are Ready to Become Experience-Orchestrated, Highlighting Lack of PersonalisationNovember 27, 2024
Investors Think Safe, but Act Bold: MyFi Report Exposes Risk Tolerance Mismatch November 27, 2024
Indkal Technologies Redefines Luxury Home Entertainment with Acer M Series Hybrid MiniLED TelevisionsNovember 27, 2024